Who
Ellen Chiniara
Director
Company insider
Files Form 4 as: Director, Compass Therapeutics; Chief Legal Officer, Kymera Therapeutics; EVP & Chief Legal Officer, Alexion Pharmaceuticals; GC, Chief Ethics Officer&Sec, Alere.
In numbers
- Trades disclosed
- 98
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $273K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 31 Dec 2007
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 3 Mar 2025filed 3 Mar 2025 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 3 Mar 2025filed 3 Mar 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 3 Mar 2025filed 3 Mar 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $56K1,833 at $30.33 | filing |
| 3 Mar 2025filed 3 Mar 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K408 at $31.00 | filing |
| 11 Feb 2025filed 13 Feb 2025 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 6 Jan 2025filed 6 Jan 2025 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $131K3,129 at $41.75 | filing |
| 1 Mar 2024filed 4 Mar 2024 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,531 at $0.00 | filing |
| 1 Mar 2024filed 4 Mar 2024 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code A | —21,755 at $0.00 | filing |
| 9 Feb 2024filed 14 Feb 2024 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 4 Jan 2024filed 5 Jan 2024 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $74K3,295 at $22.58 | filing |
| 8 Feb 2023filed 9 Feb 2023 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 26 Apr 2022filed 28 Apr 2022 | CMPX Compass Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 21 Jul 2021filed 23 Jul 2021 | Alexion Pharmaceuticals | SEC FORM 4 Code D | —116,850 at $0.00 | filing |
| 14 Jul 2021filed 16 Jul 2021 | Alexion Pharmaceuticals | SEC FORM 4 Code A | —26,812 at $0.00 | filing |
| 14 Jul 2021filed 16 Jul 2021 | Alexion Pharmaceuticals | SEC FORM 4 Code A | —27,657 at $0.00 | filing |
| 28 Feb 2021filed 2 Mar 2021 | Alexion Pharmaceuticals | SEC FORM 4 Code A | —19,321 at $0.00 | filing |
News
Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) versus ADC Therapeutics (NYSE:ADCT)KYMR · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Ellen Chiniara; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.